Femasys Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $6.4M
- Price
- $2.20
- % Change (Daily % change from the live per-ticker quote feed.)
- +1.85%
- Volume
- 147.0K
About
Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering. For diagnostic purposes, Femasys provides FemCerv, a biopsy device utilized for endocervical curettage, and FemEMB, a product candidate intended for endometrial sampling to assist in the detection of uterine cancer. Additionally, the company markets its FemVue saline-air device across various international regions, including the U.S., Europe, Canada, and Japan. Its infertility-related products are supplied to obstetrician-gynecologists, other allied healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. The company also offers a range of non-surgical product technologies.
Quick stats
Shares outstanding2.9M
Computed float2.7M
Float / shares93.9%
Cash runway (months)-1.1
Key info
SectorHealthcare
IndustryMedical - Instruments & Supplies
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001339005
Websitehttps://www.femasys.com
AI Summary
AI-generated1/10
majorbullishearnings
Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update
Femasys reported Q2 sales of $331,827, down 18.9% year-over-year, but strengthened its financial position with the closing of a $30 million private placement.
The company regained compliance with Nasdaq listing requirements and announced potential proceeds of up to $90 million if warrants are fully exercised.
Management stated the capital will support the U.S. commercial strategy for FemaSeed and the advancement of the FemBloc clinical program toward FDA approval.
Red flags
- Quarterly sales declined 18.9% year-over-year
- Cash balance was low ($1.4M) prior to the financing close